Lipoprotein(a) Response to Dietary Saturated Fat Reduction: Relationship to Apolipoprotein(a) Size Polymorphism in African Americans

Nutrients, Journal Year: 2025, Volume and Issue: 17(3), P. 426 - 426

Published: Jan. 24, 2025

Background/Objectives: An elevated lipoprotein(a) [Lp(a)] level, which is a prevalent cardiovascular risk factor, genetically determined by size polymorphism of its apolipoprotein(a) [apo(a)] component. Despite genetic control, Lp(a) level increases in response to dietary saturated fat (SFA) reduction. We tested the roles apo(a) and characteristics modulating SFA Methods: assessed 165 African Americans experiencing 24% increase resulting from reduction [16% at an average American Diet diet (AAD) 6% DASH-type diet]. Apo(a) effects were based on following factors: (1) presence small atherogenic (≤22 kringles), (2) phenotype (single or two isoforms), (3) isoform dominance, (4) tertiles combined kringle sizes. Results: There no significant differences between carriers vs. non-carriers apo(a), those with single expressed isoforms, differing dominance patterns (p > 0.05 for all). The extent differed across increasing sizes = 0.006 trend). In multivariate model, AAD was predictor changes < 0.05). Relative allele-specific level—an associated defined size—were similar spectrum. Conclusions: Reducing intake results Individuals smaller reached post-intervention compared larger sizes, some cases reclassification.

Language: Английский

---

Perspectives on early health economic evaluations of RNA therapies targeted at lipoprotein(a)

Current Opinion in Endocrinology Diabetes and Obesity, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 12, 2025

Purpose of review Early health economic evaluations new medications are useful, as they consider the implications for services. We reviewed recent literature on expected clinical outcomes lowering elevated plasma lipoprotein(a) [Lp(a)] in secondary prevention, which is essential information effectiveness evaluations. a early evaluation RNA therapies targeted at Lp(a). Recent findings RNA-based therapies, if approved, would likely be used initially adults with established atherosclerotic cardiovascular disease (ASCVD) and very high Adults ASCVD have absolute risk recurrent events Lp(a) serves risk-enhancing factor. Potent prevention may associated significant relative reductions coronary heart or events; this needs confirmation currently ongoing future trials. One has estimated value olpasiran pelacarsen, various willingness-to-pay thresholds, compared standard-of-care prevention. Summary estimate longer-term benefits cost consequences medications. Existing casual evidence can best available evidence, while awaiting results from major

Language: Английский

---

Association of Lipoprotein(a) and Coronary Artery Calcium with Atherosclerotic Cardiovascular Disease

Journal of clinical lipidology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

---

The prothrombotic effects of Lipoprotein (a) and atherosclerosis

European Journal of Internal Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

---

Association between lipoprotein(a) and long-term prognosis in patients receiving transcatheter aortic valve replacement

Journal of clinical lipidology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

---

Schlagen Frauenherzen anders? – Geschlechterunterschiede im Lipidmanagement

Deleted Journal, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

Zusammenfassung Geschlechterspezifische Unterschiede im Lipidstoffwechsel sind vor allem hormonell bedingt. Frauen haben prämenopausal Vergleich zu Männern tendenziell günstigere Lipidwerte, wie höhere Konzentrationen an High-Density-Lipoprotein-Cholesterin (HDL-C) und niedrigere Low-Density-Lipoprotein-Cholesterin (LDL-C). Mit Beginn der Menopause verschlechtern sich diese Werte jedoch durch hormonelle Veränderungen, wodurch bei das Risiko für atherosklerotische Herz-Kreislauf-Erkrankungen erhöht. Trotz vergleichbarer Wirksamkeit lipidsenkender Therapien zeigen mehrere Studien einheitlich, dass seltener die empfohlenen LDL-C-Zielwerte erreichen. Besonders in klinischen Praxis bestehen große Diskrepanzen zwischen Leitlinienempfehlungen tatsächlicher Behandlung, Hochrisikopatientinnen. Verschiedene Barrieren tragen wesentlich dazu bei: Dazu gehören Unterschätzung des Risikos behandelnde Ärzte, ein zurückhaltenderes Verordnungsverhalten, eingeschränktes Bewusstsein Notwendigkeit einer Therapie Patientinnen sowie eine verminderte Medikamentenadhärenz. Letztere wird unter anderem stärkere Wahrnehmung von Nebenwirkungen Prävalenz Statinintoleranz beeinflusst. Die Betreuung spezialisierten Lipidzentren zeigt, viele schwer einstellbare Patienten, z. B. Patienten mit oder hohen LDL-C-Ausgangswerten, gezielter Nachsorge erfolgreich behandelt werden können. Neue pharmakologische Ansätze Kombinationstherapien ermöglichen es, Therapieziele Dennoch erreichen trotz solcher Maßnahmen ihre LDL-Zielwerte, was auf intensiverer geschlechtersensibler Strategien hinweist. Eine wirksame Lipidtherapie erfordert verstärkt den Einsatz Kombinationstherapien, regelmäßige Kontrollen enge Zusammenarbeit Patient Arzt. ist es entscheidend, Therapieadhärenz verbessern mögliche konsequent anzugehen, um kardiovaskuläre effektiv senken.

---

Impact of diabetes on risk of major adverse cardiovascular events associated with lipoprotein(a) levels in patients with established atherosclerotic cardiovascular disease

European Journal of Preventive Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: March 11, 2025

Abstract Aims Lipoprotein(a) [Lp(a)] is an emerging risk factor for major adverse cardiovascular events (MACE). However, evidence on MACE according to Lp(a) level in atherosclerotic patients insufficient, and more data needed about whether type 2 diabetes (T2DM) additionally contributes this risk. We aimed investigate the association between compare magnitude of Lp(a)-MACE with without T2DM. Methods results Using a retrospective cohort study T2DM who were screened 1 January 2000 31 December 2020, we estimated stratified by quintiles compared difference presence partial likelihood ratio test. The included 25 826 established disease, whom 7535 had (29.2%) 18 291 did not (70.8%). During 160 174 person-years (PY) follow-up, total 4836 observed. Compared lowest quintile (Q) levels, multivariable-adjusted hazard ratios (HRs) 95% confidence intervals (CIs) MACEs across Q2 Q5 1.10 (95% CI: 0.94–1.30), 0.98 0.83–1.16), 1.25 1.06–1.46), 1.29 1.10–1.51) T2DM, 0.99 0.88–1.12), 0.98–1.23), 1.01 0.90–1.13), 1.13 1.01–1.27) those strength was stronger among (P &lt; 0.001). Conclusion Among elevated significantly associated higher MACE. showed excess risk, suggesting need clinical interventions concerning both glycemic control.

Language: Английский

---

Therapeutic advances in the Lp(a) battle: what do we know and what are the most awaited novelties in the field ?

Current Opinion in Lipidology, Journal Year: 2025, Volume and Issue: unknown

Published: March 20, 2025

Purpose of review To the latest advances in lipoprotein(a) [Lp(a)] treatment, focusing on impact currently available lipid-lowering therapies and highlighting highly anticipated most developed RNA-based therapies. Recent findings Lp(a) is a key genetically determined cardiovascular risk modifier linked to myocardial infarction calcific aortic stenosis development progression. Conventional have no substantial effect circulating levels, leading current guidelines focus managing traditional factors. New therapies, including antisense oligonucleotides small interfering RNAs, target Lipoprotein(A) [LPA] gene translation reduce apo(a) synthesis particles formation. The advanced candidates, pelacarsen, olpasiran, lepodisiran, shown promising reductions, ranging from −35% −101% Phase 1 2 trials. 3 studies will clarify their effects outcomes address concerns about extremely low levels safety. Summary agents lepodisiran represent developments this field. Ongoing trials, expected be finalized between 2025 2029, crucial determining efficacy improving safety profiles.

Language: Английский

---

Fettstoffwechselstörungen: Hypertriglyzeridämie und Lipoprotein(a)-Erhöhung im Fokus

Deleted Journal, Journal Year: 2025, Volume and Issue: unknown

Published: April 4, 2025

---

The effect of highly bioavailable forms of curcumin on lipoprotein(a) plasma levels: a systematic review and meta-analysis of randomized clinical studies

Prostaglandins & Other Lipid Mediators, Journal Year: 2025, Volume and Issue: 178, P. 106994 - 106994

Published: April 17, 2025

Language: Английский

---